Genfit: Tops SBF after commercial agreement with Labcorp for NASH test

Genfit SA

28/09/2020 08:54

** Shares in drug developer Genfit  GNFT.PA  jumped over 20%
after it signed an exclusive agreement with Labcorp to
commercialize a new test for liver disease  urn:newsml:reuters.com:*:nFWN2GO017
    ** Labcorp will commercialize the test - which helps
identify patients with at-risk non-alcoholic steatohepatitis
(NASH) - for clinical care use in U.S. and Canada, said Genfit
    ** NASH is a liver disease caused by a buildup of fat,
characterized by liver inflammation and damage
    ** Genfit expects the test to become available by early 2021
    ** The stock at the top of France's SBF 120  .SBF120  index

 (sarah.morland@thomsonreuters.com)